What did @ardilaq16 actually say?
This is mostly a celebration video, not a medical tutorial. The creator is reacting to a one-year body transformation, referencing someone named Chrissy who now has "a flat stomach" and tying it to what appears to be Wegovy use (per the hashtag). The line "I'm in the last laugh now" frames GLP-1 weight loss as social vindication. There are no dosage claims, no cure claims, just someone excited about visible results. That's worth noting before we pile on.
The hashtag "wagovy" is a misspelling of Wegovy, the FDA-approved brand of semaglutide 2.4mg indicated for chronic weight management. The video does not explain the drug, describe side effects, or make any clinical assertions. It is, functionally, a reaction video to a before-and-after.
Does the science back this up?
One-year body composition changes on semaglutide are real and well-documented. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed participants lost an average of 14.9% of body weight over 68 weeks on semaglutide 2.4mg versus 2.4% on placebo. A "flat stomach" after a year is a plausible outcome, not an exaggeration.
Abdominal fat, specifically visceral adiposity, tends to respond particularly well to GLP-1 receptor agonists. A secondary analysis from the STEP program found meaningful reductions in waist circumference alongside total weight loss. So when the creator reacts to a visible midsection change, that tracks with the clinical data.
What the video doesn't tell you: weight loss varies significantly by individual. Not everyone gets a dramatic transformation. The STEP 1 trial also showed about 32% of participants lost less than 5% of body weight, meaning a substantial minority sees modest results.
What did they get wrong (or right)?
There's nothing clinically incorrect here, because nothing clinical was actually claimed. The creator didn't say Wegovy cures anything, didn't recommend a dose, didn't compare compounded semaglutide to the brand. Give credit where it's due: this is a personal reaction, not a prescription guide.
The potential issue is framing. Presenting GLP-1 results as a "revenge body" narrative, something earned to make an ex regret, can set up unrealistic expectations. Weight loss on semaglutide is real, but it requires consistent use, lifestyle support, and medical supervision. It also frequently reverses after discontinuation. Davies et al. (2022, Diabetes, Obesity and Metabolism) found participants regained roughly two-thirds of their lost weight within a year of stopping semaglutide.
The "last laugh" framing also skips the part where GLP-1 medications come with significant gastrointestinal side effects, cost barriers, and access challenges that don't make for good TikTok content but matter enormously for real patients.
What should you actually know?
If you saw this video and thought "I want that too," here's the unfiltered version. Semaglutide 2.4mg (Wegovy) produces meaningful weight loss in most people who stay on it, and that is genuinely good news for a drug class that works better than most of what came before it. But it is a chronic medication, not a one-time fix.
Stopping the drug typically means regaining the weight. The STEP 4 trial (Rubino et al., 2021, JAMA) found participants who switched from semaglutide to placebo after 20 weeks regained an average of 6.9 percentage points of body weight over the following 48 weeks. The drug works while you're on it. That's a nuance the "last laugh" framing doesn't capture.
Access is also a real barrier. Wegovy has faced supply shortages, and out-of-pocket costs can exceed $1,300 per month without insurance coverage. Compounded semaglutide has filled some of that gap, but compounded versions are not FDA-approved, are not equivalent to Wegovy, and carry their own risks. Anyone considering this medication should be working with a licensed provider, not sourcing based on a TikTok reaction.